Larimar Therapeutics (LRMR) Capital Expenditures (2013 - 2025)

Larimar Therapeutics (LRMR) has reported Capital Expenditures for 13 consecutive years, with $23000.0 the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Capital Expenditures fell 62.9% year-over-year to $23000.0; the trailing twelve-month figure through Dec 2025 stood at $91000.0 (down 82.33% YoY), and the FY2025 full-year result was $91000.0, down 82.33% from the prior year.
• Capital Expenditures improved to $23000.0 in Q3 2025 per LRMR's latest filing, from $19000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $331000.0 in Q1 2021 and bottomed at -$36000.0 in Q2 2021.
• Historically, Capital Expenditures has averaged $75187.5 across 5 years, with a median of $26000.0 in 2021.
• The sharpest annual moves came in 2023 and 2024: Capital Expenditures slumped 106.0% in 2023, then jumped 2025.0% in 2024.
• Over 5 years, Capital Expenditures stood at $9000.0 in 2021, then surged by 1011.11% to $100000.0 in 2022, then surged by 68.0% to $168000.0 in 2023, then gained by 6.55% to $179000.0 in 2024, then slumped by 87.15% to $23000.0 in 2025.
• According to Business Quant data, Capital Expenditures over the past three periods registered $23000.0, $19000.0, and $49000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.